Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

DAPA-HF Trial Comm Investigators, J. J. V. McMurray*, S. D. Solomon, S. E. Inzucchi, L. Kober, M. N. Kosiborod, F. A. Martinez, P. Ponikowski, M. S. Sabatine, I. S. Anand, J. Belohlavek, M. Bohm, C. -E. Chiang, V. K. Chopra, R. A. de Boer, A. S. Desai, M. Diez, J. Drozdz, A. Dukat, J. GeJ. G. Howlett, T. Katova, M. Kitakaze, C. E. A. Ljungman, B. Merkely, J. C. Nicolau, E. O'Meara, M. C. Petrie, P. N. Vinh, M. Schou, S. Tereshchenko, S. Verma, C. Held, D. L. DeMets, K. F. Docherty, P. S. Jhund, O. Bengtsson, M. Sjostrand, A. -M. Langkilde

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

1042 Citaten (Scopus)

Samenvatting

BACKGROUND

In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.

METHODS

In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death.

RESULTS

Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P

CONCLUSIONS

Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes.

Originele taal-2English
Pagina's (van-tot)1995-2008
Aantal pagina's14
TijdschriftNew England Journal of Medicine
Volume381
Nummer van het tijdschrift21
DOI's
StatusPublished - 21-nov-2019

Citeer dit